Maidenhead, 23rd April 2010 - Following the Joint Committee on Vaccination and Immunisation's
recommendation for the introduction of a shingles vaccination programme for people aged 70 to 79
years, conditional on the vaccine being purchased at a cost-effective price,1 Sanofi Pasteur MSD is
committed to bring Zostavax®, the only licensed herpes zoster vaccine, to the UK as soon as
possible. The procurement exercise to purchase the vaccine was announced by the Department of
Health on 31st January 2010.
Maidenhead, 30th June 2010 - The Committee for Medicinal Products for Human Use (CHMP)
of the European Medicines Agency (EMA) gives a positive opinion for extending the indication
of the four-type (6,11,16,18) human papillomavirus (HPV) vaccine Gardasil® for use in women
up to the age of 45 yearsi.
Severe rotavirus disease reduced by 93% at one year and 89% at two years.
Maidenhead, 24 May 2010 - the recent Cochrane Systematic Review1 published May 2010 demonstrates the longlasting
and effective protection against severe rotavirus disease in infants delivered by RotaTeq® [Rotavirus vaccine
(live, oral)] in an analysis that compared rotavirus vaccines with placebo.
Maidenhead, 18th February 2010 - Having demonstrated good efficacy in women up to age 26, the four-type vaccine confirmed
strong efficacy in preventing cervical lesions and pre-cancers and external genital lesions in
women up to age 45.
Maidenhead, 8th May, 2009 –
The four-type HPV vaccine Gardasil® demonstrates real life benefits
Maidenhead, 14th October, 2009 –
Seasonal flu vaccination remains necessary to protect vulnerable populations
from seasonal influenza during a pandemic
Maidenhead, 14th September 2009 – The product information of the four-type (6,11,16,18)
human papillomavirus (HPV) vaccine Gardasil® has been updated to include the clinical efficacy
and safety information of the vaccine for women up to 45 years of age.*1
Maidenhead, 29 May 2009 - The four-type (6, 11, 16, 18) human papillomavirus (HPV) vaccine,
Gardasil® has been awarded World Health Organization (WHO) pre-qualification. It is the first
cervical cancer vaccine to receive WHO pre-qualification.
Maidenhead, 8th May, 2009 – New results from an extended follow-up study further support the
evidence that protection provided by the four-type (6,11,16,18) human papillomavirus (HPV)
vaccine Gardasil® should be long-lasting.
